國立虎尾科技大學 |

Myelodysplastic syndromes = diagnosis - prognosis - therapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Myelodysplastic syndromes/ edited by Uwe Platzbecker, Pierre Fenaux.
其他題名:	diagnosis - prognosis - therapy /
其他作者:	Platzbecker, Uwe.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	v, 157 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Myelodysplastic syndromes - Diagnosis. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-76879-3
ISBN:	9783319768793

Myelodysplastic syndromes = diagnosis - prognosis - therapy /
Myelodysplastic syndromesdiagnosis - prognosis - therapy /[electronic resource] :edited by Uwe Platzbecker, Pierre Fenaux. - Cham :Springer International Publishing :2018. - v, 157 p. :ill., digital ;24 cm. - Hematologic malignancies,2197-9766. - Hematologic malignancies..

Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation.

This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.

ISBN: 9783319768793

Standard No.: 10.1007/978-3-319-76879-3doiSubjects--Topical Terms:

1206499
Myelodysplastic syndromes
--Diagnosis.

LC Class. No.: RC645.73 / .M945 2018

Dewey Class. No.: 616.41

Myelodysplastic syndromes = diagnosis - prognosis - therapy /
LDR:02589nam a2200325 a 4500 001 927297
003 DE-He213
005 20190111102510.0
006 m d
007 cr nn 008maaau
008 190626s2018 gw s 0 eng d
020 $a 9783319768793 $q (electronic bk.)
020 $a 9783319768786 $q (paper)
024 7 $a 10.1007/978-3-319-76879-3 $2 doi
035 $a 978-3-319-76879-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC645.73 $b .M945 2018
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
082 0 4 $a 616.41 $2 23
090 $a RC645.73 $b .M996 2018
245 0 0 $a Myelodysplastic syndromes $h [electronic resource] : $b diagnosis - prognosis - therapy / $c edited by Uwe Platzbecker, Pierre Fenaux.
260 $a Cham : $c 2018. $b Springer International Publishing : $b Imprint: Springer,
300 $a v, 157 p. : $b ill., digital ; $c 24 cm.
490 1 $a Hematologic malignancies, $x 2197-9766
505 0 $a Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation.
520 $a This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
650 0 $a Myelodysplastic syndromes $x Diagnosis. $3 1206499
650 0 $a Myelodysplastic syndromes $x Treatment. $3 1206500
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Hematology. $3 645254
650 2 4 $a Oncology. $3 593951
700 1 $a Platzbecker, Uwe. $3 1206497
700 1 $a Fenaux, Pierre. $3 1206498
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Hematologic malignancies. $3 890317
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-76879-3
950 $a Medicine (Springer-11650)